Advertisement

 

 

Antiretroviral resistance following immunological monitoring in a resource-limited setting of western India: A cross-sectional study.

Antiretroviral resistance following immunological monitoring in a resource-limited setting of western India: A cross-sectional study.
Author Information (click to view)

Karade SK, Kulkarni SS, Ghate MV, Patil AA, Londhe R, Salvi SP, Kadam DB, Joshi RK, Rewari BB, Gangakhedkar RR,


Karade SK, Kulkarni SS, Ghate MV, Patil AA, Londhe R, Salvi SP, Kadam DB, Joshi RK, Rewari BB, Gangakhedkar RR, (click to view)

Karade SK, Kulkarni SS, Ghate MV, Patil AA, Londhe R, Salvi SP, Kadam DB, Joshi RK, Rewari BB, Gangakhedkar RR,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

PloS one 2017 08 0112(8) e0181889 doi 10.1371/journal.pone.0181889

Abstract
BACKGROUND
The free antiretroviral therapy (ART) program in India still relies on the clinico-immunological monitoring for diagnosis of treatment failure. As the nucleoside reverse transcriptase inhibitor (NRTI) backbone is shared in first- and second-line regimens, accumulation of drug resistant mutations (DRMs) can compromise the efficacy of NRTI. This study was undertaken to describe the pattern of HIV DRMs following immunological monitoring and investigate its impact on the cycling of NRTI between first- and second-line ART.

METHODS AND FINDINGS
This cross-sectional study was performed at a state-sponsored ART clinic of Pune city in western India between January and June 2016. Consecutive adults receiving first-line ART with immunological failure (IF) were recruited for plasma viral load (PVL) estimation. Randomly selected 80 participants with PVL >1000 copies/mL underwent HIV drug resistance genotyping. Of these, 75 plasma sample were successfully genotyped. The median CD4 count and duration of ART at the time of failure were 98 (IQR: 61.60-153.50) cells/μL and 4.62 (IQR: 3.17-6.15) years, respectively. The prevalence of NRTI, non-NRTI, and major protease inhibitor resistance mutations were 89.30%, 96%, and 1.33%, respectively. Following first-line failure, sequences from 56.67% of individuals indicated low- to high-level resistance to all available NRTI. The proportion of sequences with ≥2 thymidine analogue mutations (TAMs) and ≥3 TAMs were 62.12% and 39.39%, respectively. An average of 1.98 TAMs per sequence were observed following IF as compared to 0.37 TAMs per sequence following targeted PVL monitoring at 12 months of ART from a prior study; this difference was significant (p<0.001). CONCLUSION
The option of cycling of NRTI analogues between first- and second-line regimens would no longer be effective if individuals are followed-up by immunological monitoring due to accumulation of mutations. Introduction of routine PVL monitoring is a priority for the long-term sustainability of free ART program in India.

Submit a Comment

Your email address will not be published. Required fields are marked *

3 × five =

[ HIDE/SHOW ]